Drug Trial Radar · NCT07409272
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
614
Planned (sponsor's estimate)
Start
Feb 17, 2026
Primary completion
Aug 31, 2029
Study completion Aug 31, 2029
Sponsor
- Lead sponsor
- Astellas Pharma Global Development, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Feb 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Pancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic). The standard treatment is chemotherapy, but other treatments are needed to improve outcomes in people with pancreatic cancer. The first treatment that people usually receive is chemotherapy. At the time this study started, some of the main standard chemotherapies for pancreatic cancer were mFOLFIRINOX or NALIRIFOX. Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in certain genes, making them faulty. Many people with pancreatic cancer have a faulty KRAS gene. One such change in the KRAS gene is called a G12D mutation. Researchers are looking for ways to stop the actions of abnormal proteins made from the KRAS G12D mutation. This study is about setidegrasib given with chemotherapy in people with pancreatic cancer who have the KRAS G12D mutation. Before setidegrasib can become an approved treatment, clinical studies need to be completed to understand how it works and how safe it is. The main aim is to learn if people who are given setidegrasib with chemotherapy live for longer than people who are given placebo with chemotherapy. Other aims are to learn if setidegrasib delays the cancer and symptoms returning, how the body processes setidegrasib, and its safety, when given with chemotherapy. People in this study will be adults with metastatic pancreatic cancer with the G12D mutation in their KRAS gene. Surgery or radiotherapy will not be an option to cure their cancer. People cannot take part if the cancer cells have spread to the thin tissue covering the brain and spinal cord (leptomeningeal disease), have symptoms of cancer in the brain or nervous system, or have recently had some other cancers that required treatment. In this study, people are given either setidegrasib with mFOLFIRINOX or NALIRIFOX chemotherapy, or a placebo with mFOLFIRINOX or NALIRIFOX chemotherapy. Whether people receive setidegrasib or placebo is decided by chance. The study doctor decides which chemotherapy (mFOLFIRINOX or NALIRIFOX) people receive. People will only receive NALIRIFOX chemotherapy (with setidegrasib or placebo) after the safety of setidegrasib with NALIRIFOX chemotherapy has been confirmed in another ongoing setidegrasib study. All of the study treatments are given slowly through a tube into a vein (infusion). People will continue to receive study treatment until their cancer gets worse, they can't tolerate the study treatment, they start other cancer treatment, they or the doctor decides the person should stop receiving study treatment, or sadly they pass away. There will be safety checks at each visit, and the doctors will continue to check for medical problems and people's wellbeing throughout the study.
Conditions
- Pancreatic Cancer
- Metastatic Pancreatic Cancer
- Metastatic Pancreatic Adenocarcinoma
Interventions
SetidegrasibDrug
Intravenous infusion
OxaliplatinDrug
Intravenous infusion
LeucovorinDrug
Intravenous infusion
IrinotecanDrug
Intravenous infusion
fluorouracilDrug
Intravenous infusion
liposomal irinotecanDrug
Intravenous infusion
PlaceboDrug
Intravenous Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Up to 3.5 years
Locations
104 sites in 11 countries. Site status is shown where the registry gives one.
Banner Gateway Medical Center - Banner MD Anderson Cancer Center
Gilbert, Arizona · Recruiting
University of Arizona Cancer Center - North Campus
Tucson, Arizona · Recruiting
Mercy Cancer Center
Fort Smith, Arkansas · Recruiting
Crosson Cancer Institute at Providence St. Jude Medical Center in Fullerton
Fullerton, California · Recruiting
UCI Health - Irvine
Irvine, California · Recruiting
Cedars-Sinai - Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
Hoag Mem Hosp Presbyterian
Newport Beach, California · Recruiting
UC Irvine Health-Chao Family Comprehensive Cancer Center
Orange, California · Recruiting
Hartford Healthcare
Hartford, Connecticut · Recruiting
Baptist MD Anderson Cancer Institute
Jacksonville, Florida · Recruiting
Baptist Health Medical Group Oncology
Miami, Florida · Recruiting
Mount Sinai Medical Center - Miami Beach
Miami Beach, Florida · Recruiting
AdventHealth, Orlando
Orlando, Florida · Recruiting
Piedmont Healthcare - Piedmont Physicians Medical Oncology Atlanta
Atlanta, Georgia · Recruiting
Indiana University Health - Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana · Recruiting
Hematology Oncology of Indiana
Indianapolis, Indiana · Recruiting
Saint Elizabeth Medical Center, Inc. DBA St. Elizabeth Health Care
Edgewood, Kentucky · Recruiting
University of Maryland School - Division of Hematology/Oncology
Baltimore, Maryland · Recruiting
University of Michigan Health - University of Michigan Medical Center
Ann Arbor, Michigan · Recruiting
Henry Ford Cancer, Detroit
Detroit, Michigan · Recruiting
Allina Health Cancer Institute - Hematology Cancer Care Services
Minneapolis, Minnesota · Recruiting
HealthPartners Frauenshuh Cancer Center
Saint Louis Park, Minnesota · Recruiting
HealthPartners Cancer Center at Regions Hospital
Saint Paul, Minnesota · Recruiting
Mercy CH Chub O'Reilly Cancer Center
Springfield, Missouri · Recruiting
The Alvin J. Siteman Cancer Center - Center for Advanced Med
St Louis, Missouri · Recruiting
Mercy David C. Pratt Cancer Center - St. - Mercy Research - David C. Pratt Cancer Center
St Louis, Missouri · Recruiting
Saint Joseph Hospital - Cancer Centers - St. Vincent Frontier Cancer Center
Billings, Montana · Recruiting
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire · Recruiting
Memorial Sloan Kettering - Hackensack - Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey · Recruiting
Memorial Sloan Kettering Cancer Center - Monmouth
Middletown, New Jersey · Recruiting
Memorial Sloan Kettering Bergen
Montvale, New Jersey · Recruiting
Atlantic Health - Overlook Medical Center
Morristown, New Jersey · Recruiting
Roswell Park Comprehensive Cancer Center
Buffalo, New York · Recruiting
Memorial Sloan Kettering Commack
Commack, New York · Recruiting
Memorial Sloan Kettering Westchester
Harrison, New York · Recruiting
NYU Long Island Mineola
Mineola, New York · Recruiting
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center - Main Campus
New York, New York · Recruiting
University of Rochester
Rochester, New York · Recruiting
Stony Brook Medicine - Stony Brook Cancer Center
Stony Brook, New York · Recruiting
Showing 40 of 104 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.